Mutations in Kirsten rat sarcoma 2 viral oncogene homolog (KRAS), neuroblastoma RAS viral oncogene homolog (NRAS), and BRAF account for 50% of all cases at presentation and these numbers increase at relapse MM [58]. This evidence concerns the gene NRAS and Miyoshi myopathy.